Mesenchymal stem cell therapy - Genesis

Drug Profile

Mesenchymal stem cell therapy - Genesis

Alternative Names: Allogeneic human umbilical cord tissue-derived mesenchymal stem cells

Latest Information Update: 21 Jan 2016

Price : $50

At a glance

  • Originator Genesis
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple sclerosis

Most Recent Events

  • 03 Nov 2015 Genesis terminates a phase I/II trial in Multiple sclerosis in Trinidad and Tobago due to lack of funds (NCT02418325)
  • 01 Feb 2015 Phase-I/II clinical trials in Multiple sclerosis (Recurrent) in Trinidad and Tobago (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top